Please login to the form below
paclitaxel
This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
The study indicated that the chemotherapy used was down to the physician's choice of either paclitaxel or doxorubicin.
Latest news
-
Merck receives first breast cancer approval in Europe for Keytruda
Keytruda can now be used as first-line treatment in combination with chemotherapy – investigator’s choice of paclitaxel, nab-paclitaxel or gemcitabine/carboplatin – to treat locally recurrent unresectable or metastatic
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Keytruda plus Lenvima treatment also led to an objective response rate (ORR) of 30% versus 15% for patients receiving either doxorubicin or paclitaxel. ... Patients receiving Merck and Eisai’s treatment had a complete response rate of 5% compared with 3
-
BMS’ Opdivo wins EU approval for second-line oesophageal cancer
The EC approved Opdivo following positive results from the phase 3 ATTRACTION-3 trial, which investigated the PD-1 inhibitor versus chemotherapy docetaxel or paclitaxel – as a treatment for patients with
-
Tecentriq combo fails in advanced triple negative breast cancer
Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... The phase 3 Impassion131 study evaluated
-
Tecentriq misses the mark in advanced ovarian cancer
The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer.
More from news
Approximately 9 fully matching, plus 122 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
-
Pharma deals in May 2015
Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
-
The rise of chronic disease in BRIC markets
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Current chemotherapy treatment options for ovarian cancer are fairly standard. After debulking surgery, the patient will undergo their first line of chemotherapy; the standard of care involves a combination of paclitaxel
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- First evidence-based guide launched to put patients at heart of digital innovations
- Roche shares new positive Ocrevus data for MS patients
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- A creative awakening – how pharma is bringing innovation to the patient journey
- Country report: The healthcare market in South Korea
- European Commission approves potential new treatment for Pompe disease
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
